PPA
BTAI

Parametric Portfolio Associates’s BioXcel Therapeutics BTAI Stock Holding History

Parametric Portfolio Associates’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-720
Closed -$350K – 3647
2021
Q3 		$350K Buy
720
+128
+22% +$56.3K ﹤0.01% 3241
2021
Q2 		$275K Buy
592
+1
+0.2% +$545 ﹤0.01% 3298
2021
Q1 		$408K Buy
591
+242
+69% +$195K ﹤0.01% 3589
2020
Q4 		$258K Sell
349
-37
-10% -$28.8K ﹤0.01% 3669
2020
Q3 		$268K Sell
386
-7
-2% -$5.26K ﹤0.01% 3534
2020
Q2 		$333K Buy
+393
New +$256K ﹤0.01% 3428

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Parametric Portfolio Associates's BTAI Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 720 shares — an estimated $350K sold.

Parametric Portfolio Associates first reported a position in BTAI in Q2 2020 and held it in 6 quarters. The position peaked at $408K in Q1 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 720 BioXcel Therapeutics shares in Q4 2021, an estimated $350K.
  • Parametric Portfolio Associates first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 6 quarters.
  • Parametric Portfolio Associates's BioXcel Therapeutics position peaked at $408K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.